Legend Biotech Corp
LEGN34.660USD
+0.380+1.11%
Market hours （ET）Quotes delayed by 15 min
6.37BMarket Cap
LossP/E TTM
More Details of Legend Biotech Corp Company
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Company Info
Company codeLEGN
Company nameLegend Biotech Corp
IPO dateJun 04, 2020
Founded at2015
CEODr. Ying Huang, Ph.D.
Number of employees2600
Security typeDepository Receipt
Fiscal year-endJun 04
Address2101 Cottontail Lane
CitySOMERSET
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code08873
Phone17328505598
Websitehttps://investors.legendbiotech.com/
Company codeLEGN
IPO dateJun 04, 2020
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
579.05M
92.32%
Europe
47.87M
7.63%
China
320.00K
0.05%
By Business
By Region
No Data
Shareholder
Update time: Sat, Apr 26
Update time: Sat, Apr 26
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Fidelity Management & Research Company LLC
6.38%
RA Capital Management, LP
4.09%
T. Rowe Price Associates, Inc.
3.70%
HHLR Advisors, Ltd.
3.26%
Westfield Capital Management Company, L.P.
3.11%
Other
79.46%
Shareholder Statistics
Shareholder
Proportion
Fidelity Management & Research Company LLC
6.38%
RA Capital Management, LP
4.09%
T. Rowe Price Associates, Inc.
3.70%
HHLR Advisors, Ltd.
3.26%
Westfield Capital Management Company, L.P.
3.11%
Other
79.46%
Type
Shareholder
Proportion
Investment Advisor
19.55%
Investment Advisor/Hedge Fund
18.45%
Hedge Fund
13.79%
Research Firm
2.70%
Corporation
1.25%
Venture Capital
0.53%
Bank and Trust
0.30%
Sovereign Wealth Fund
0.09%
Individual Investor
0.08%
Other
43.26%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
539
104.38M
56.84%
-4.11M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
2023Q1
421
72.14M
43.70%
-3.07M
2022Q4
415
67.29M
40.76%
-7.51M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
11.71M
6.38%
-4.86M
-29.35%
Dec 31, 2024
RA Capital Management, LP
7.51M
4.09%
--
--
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.80M
3.7%
-4.36M
-39.04%
Dec 31, 2024
HHLR Advisors, Ltd.
5.98M
3.26%
-651.95K
-9.82%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.71M
3.11%
+675.19K
+13.40%
Dec 31, 2024
Suvretta Capital Management, LLC
3.50M
1.9%
+3.50M
--
Dec 31, 2024
Invesco Advisers, Inc.
3.29M
1.79%
+1.02M
+45.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.26M
1.77%
-21.07K
-0.64%
Dec 31, 2024
Braidwell LP
2.98M
1.62%
+1.44M
+93.18%
Dec 31, 2024
Citadel Advisors LLC
2.90M
1.58%
+1.59M
+120.64%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Harbor Health Care ETF
7.94%
Matthews Emerging Markets Sustainable Future Active ETF
4.28%
Matthews Emerging Markets Discovery Active ETF
3.82%
Global X Genomics & Biotechnology ETF
3.72%
Tema Oncology ETF
2.77%
KraneShares MSCI All China Health Care Index ETF
1.77%
Virtus LifeSci Biotech Products ETF
1.59%
Range Cancer Immunotherapy ETF
1.2%
iShares Biotechnology ETF
0.4%
WisdomTree China ex-State-Owned Enterprises Fund
0.31%
View more
Harbor Health Care ETF
Proportion7.94%
Matthews Emerging Markets Sustainable Future Active ETF
Proportion4.28%
Matthews Emerging Markets Discovery Active ETF
Proportion3.82%
Global X Genomics & Biotechnology ETF
Proportion3.72%
Tema Oncology ETF
Proportion2.77%
KraneShares MSCI All China Health Care Index ETF
Proportion1.77%
Virtus LifeSci Biotech Products ETF
Proportion1.59%
Range Cancer Immunotherapy ETF
Proportion1.2%
iShares Biotechnology ETF
Proportion0.4%
WisdomTree China ex-State-Owned Enterprises Fund
Proportion0.31%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data